Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Defining COX-2 inhibitors.

P E Lipsky1

  • 1University of Texas Southwestern Medical Center at Dallas, 75235-8884, USA.

The Journal of Rheumatology. Supplement
|October 14, 2000
PubMed
Summary
This summary is machine-generated.

New cyclooxygenase-2 (COX-2) specific inhibitors offer safer treatment for osteoarthritis and rheumatoid arthritis. Understanding their classification is crucial for clinicians due to distinct outcomes compared to traditional NSAIDs.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A critical review of clinical trials in systemic lupus erythematosus.

Lupus·2016
Same author

Drug repositioning in SLE: crowd-sourcing, literature-mining and Big Data analysis.

Lupus·2016
Same author

Accessory cells unrelated to mononuclear phagocytes and not of bone marrow origin.

Immunology today·2014
Same author

Interleukin 21 as a target of intervention in autoimmune disease.

Annals of the rheumatic diseases·2008
Same author

Age-related impairment of T cell proliferative responses related to the decline of CD28+ T cell subsets.

Archives of gerontology and geriatrics·2008
Same author

Measurement of human and murine interleukin 2 and interleukin 4.

Current protocols in immunology·2008
Same journal

GRAPPA 2019 Research Recipient Awards Report.

The Journal of rheumatology. Supplement·2021
Same journal

GRAPPA Treatment Recommendations: An Update From the 2020 GRAPPA Annual Meeting.

The Journal of rheumatology. Supplement·2021
Same journal

GRAPPA Patient Research Partner Network: Update to the GRAPPA 2020 Annual Meeting.

The Journal of rheumatology. Supplement·2021
Same journal

Instruments Measuring Physical Function for Psoriatic Arthritis Endorsed at GRAPPA 2020 Annual Meeting: Updates of the GRAPPA-OMERACT Working Group.

The Journal of rheumatology. Supplement·2021
Same journal

GRAPPA 2020 Update From the Education Committee.

The Journal of rheumatology. Supplement·2021
Same journal

The Role of Ultrasound in Research and Clinical Practice in Psoriatic Arthritis: Highlights From the GRAPPA Ultrasound Workshop.

The Journal of rheumatology. Supplement·2021
See all related articles

Area of Science:

  • Biochemistry and Pharmacology
  • Inflammation and Pain Pathways

Background:

  • Arachidonic acid metabolism involves two cyclooxygenase (COX) isoforms: COX-1 (constitutive) and COX-2 (inducible).
  • Nonsteroidal anti-inflammatory drugs (NSAIDs) exert anti-inflammatory, analgesic, and antipyretic effects by inhibiting COX-2.
  • NSAIDs also cause gastrointestinal side effects due to COX-1 inhibition.

Purpose of the Study:

  • To introduce the newly approved COX-2 specific inhibitors for osteoarthritis (OA) and rheumatoid arthritis (RA).
  • To highlight the importance of understanding the classification of these novel therapeutic agents.
  • To emphasize the clinical significance of differentiating COX-2 inhibitors from traditional NSAIDs.

Main Methods:

  • Review of the biochemical pathways of arachidonic acid metabolism.

Related Experiment Videos

  • Analysis of the pharmacological actions of NSAIDs and COX-2 inhibitors.
  • Comparison of clinical outcomes between NSAIDs and specific COX-2 inhibitors.

    • Main Results:

    • The development of COX-2 specific inhibitors represents a new class of therapeutic agents.
    • These agents are approved for treating osteoarthritis (OA) and rheumatoid arthritis (RA).
    • Clinical outcomes of COX-2 inhibitors differ significantly from those of NSAIDs.

    Conclusions:

    • COX-2 specific inhibitors offer a potentially safer alternative for managing OA and RA.
    • Clinicians must understand the classification and distinct properties of these new drugs.
    • Knowledge of COX-2 inhibitor mechanisms is essential for effective and safe patient treatment.